Published in Am J Cancer Res on December 15, 2014
The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 10.08
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
Multiple myeloma. Blood (2008) 5.88
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 3.41
Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet (2008) 3.29
Pax5: the guardian of B cell identity and function. Nat Immunol (2007) 3.15
Molecular programming of B cell memory. Nat Rev Immunol (2011) 2.73
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity (2007) 2.61
Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol (1998) 2.10
Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol (2009) 2.09
B cell memory and the long-lived plasma cell. Curr Opin Immunol (1999) 2.03
Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol (1998) 1.55
Activation of memory and virgin B cell clones in hyperimmune animals. Eur J Immunol (1987) 1.54
A division-linked mechanism for the rapid generation of Ig-secreting cells from human memory B cells. J Immunol (2003) 1.53
A novel NDUFA1 mutation leads to a progressive mitochondrial complex I-specific neurodegenerative disease. Mol Genet Metab (2009) 1.47
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res (2009) 1.44
Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood (1992) 1.42
Multiple myeloma cancer stem cells. J Clin Oncol (2008) 1.39
Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses. Proc Natl Acad Sci U S A (2007) 1.38
The immortality of humoral immunity. Immunol Rev (2010) 1.33
Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Exp Hematol (2002) 1.15
Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) (2009) 1.15
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica (2012) 1.14
Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol (1994) 1.14
Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med (2008) 1.11
The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res (2010) 1.09
SF3B1 mutations in chronic lymphocytic leukemia. Blood (2013) 1.08
eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways. Cell Cycle (2010) 1.07
Cancer stem cells in multiple myeloma. Cancer Lett (2008) 1.06
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood (2003) 1.04
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res (2004) 0.98
Reduced expression and loss of heterozygosity of the SDHD gene in colorectal and gastric cancer. Oncol Rep (2003) 0.96
Critical role of AKT protein in myeloma-induced osteoclast formation and osteolysis. J Biol Chem (2013) 0.95
Phase specific functions of the transcription factor TFII-I during cell cycle. Cell Cycle (2009) 0.95
CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood (1997) 0.91
Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem (2010) 0.90
Arabidopsis thaliana proliferating cell nuclear antigen has several potential sumoylation sites. J Exp Bot (2012) 0.90
The biology of multiple myeloma. J Cancer Res Clin Oncol (2000) 0.87
The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr Pharm Des (2014) 0.85
The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis. BMC Cancer (2012) 0.84
Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. PLoS One (2012) 0.82
Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study. Hematol Rep (2012) 0.81
Increased serum level of RPMPS-1/S27 protein in patients with various types of cancer is useful for the early detection, prevention and therapy. Cancer Genomics Proteomics (2012) 0.79
Association of TAP1 and TAP2 gene polymorphisms with hematological malignancies. Asian Pac J Cancer Prev (2013) 0.78
Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR. Genes Chromosomes Cancer (2013) 0.77
Multiethnic myeloma. Blood (2013) 0.77
Transcriptional analysis of hnRNPA0, A1, A2, B1, and A3 in lung cancer cell lines in response to acidosis, hypoxia, and serum deprivation conditions. Exp Lung Res (2013) 0.76